

Index

- abdomen 9–13, 158, 162, 207–45
abdominal X-rays 158, 162
ABO blood groups 258–62, 294
ACE inhibitors 49, 52–3, 57, 103,
 121, 123–6, 341–2, 346
aciclovir 103–4
acid-base balance 24–57, 97–8, 105–7,
 126–7, 129, 143, 229–31
acidosis 26, 36, 41–2, 98, 106, 108–13,
 123, 127, 129, 142, 159, 163,
 182–4, 304–5, 321, 340, 346
activated partial thromboplastin time
 (APTT) 147
active-transport reabsorption
 mechanism, concepts 29–31
Acute Dialysis Quality Initiative
 (ADQI) 104
acute intermittent haemodialysis, AKI
 management 108–9, 333–4
acute interstitial nephritis, concepts
 101–2
acute kidney injury (AKI) 4, 43,
 97–115, 117, 124, 136–63,
 177–8, 332–5, 384–91
Acute Kidney Injury Network
 (AKIN) 104–5, 108
acute rejections, concepts 294–7,
 299–301
acute tubular necrosis (ATN) 102–3,
 162, 272–3, 295–7, 299
acute-on-chronic renal failure 99
adenosine triphosphate (ATP) 30
adolescence 334–5
adrenal cortex 33–5, 47
adrenaline 159, 199
advance planning, nondialytic
 options 313–18
advanced glycosylation endproducts
 (AGEs) 49
advanced kidney disease, patient and
 carer involvement 65–6
afferent arteriole 27–57, 103
African-Caribbean patients 117–18,
 122
after-donation care for families
 267–8, 299
AGES *see* advanced glycosylation
 endproducts
air embolism complications 199–202
AKI *see* acute kidney injury
alanine aminotransferase 144
albumin 29, 46–8, 101–4, 113,
 118–21, 140, 144, 152, 194–5,
 322–35, 357–60
albuminuria 49–50, 118–21, 125–6
alcohol effects 25, 37, 43, 255, 317,
 342, 367
alcohol hand rubs 238
aldosterone 30–1, 33–6, 47
alkaline phosphate (ALP) 144
alkalosis 26, 36, 41–2
allergies 159–60, 198–202, 326–7
Allis-Chalmers Corporation 5
altruism, living donors 274–5
aluminium 3, 182–4
Alwall kidney 6
American Society for Artificial
 Internal Organs 12
amino acids 13, 29, 30, 230, 235,
 338–68
ammonium 26, 41–2
amyloidosis 46, 57, 152
anaemia 12, 16, 42, 56, 86–7, 98, 127,
 130, 133, 136, 145–50, 182–4,
 325–6, 341–3, 347, 357–9, 386
analgesics 52, 101–4, 237, 297, 299,
 316–18
anaphylaxis 100–4, 113, 159, 199
anastomosis 171–202
aneurysms 43, 55, 57, 163, 173–202
angioplasty of the renal artery 44
angiotensin I 35–6
angiotensin II 34–6, 123
angiotensin receptor blockers (ARBs)
 49, 121, 123–6, 346
anorexia 314, 323, 367–8
antecubital vein 176–202
anti-GBM disease 112, 145
antibiotics 53–4, 62, 101–2, 178–9,
 194–5, 216–18, 238–43, 253,
 298–9, 300–1
antibodies 50–3, 145, 257–97
antibody-mediated rejection (ABMR)
 294–7
anticoagulants 2–3, 4–5, 7–8, 48,
 139, 156–7, 163, 179, 187–8,
 200, 236, 240–2
antiembolic stockings 48
antihistamines 159–60, 199, 317
antihypertensives 86, 123–4, 193,
 341–2
antilymphocyte globulin (ALG) 291–4
antineutrophil cytoplasmic antibody
 test (ANCA) 145
antiproliferative agents 292–4
antirejection drugs 64–5, 68, 86,
 91–2, 289–94
antithymocyte globulin (ATG) 291–4,
 301
anxiety 67, 80, 81, 83, 86, 122, 130,
 174, 256, 281, 285–8, 297–9,
 301, 311–18, 323
aorta 271–3
APD *see* automated PD
aperients 216, 236, 299, 316, 346
aPD *see* assisted PD
appearance of urine 25, 26, 151
Appel, Kenneth 8
applied anatomy 20–58, 321
apps 70–4
arcuate arteries 27–57
arcuate veins 27–57
'area puncture' technique 173–7

- arteriosclerosis 43, 44, 49, 89–90, 224–5, 343
 arteriovenous fistula (AVF) 8, 83, 86, 132–3, 138, 170–202, 287, 305, 331–5, 390
 arteriovenous graft (AVG) 83, 170–1, 175, 176–202
 arteriovenous shunt (AV), history 8
 arthritis 13
 aspirin 123–4, 157, 299
 assisted PD (aPD) 82, 207
 asthma 159
 asystolic donations (nonheart beating) 264–5
 atherosclerosis 44, 343
Atlas of Variation 384
 atrial natriuretic peptide 33–5
 audits, quality improvements in renal nursing 382, 389–91
 autoimmune diseases 50–3
 automated PD (APD) 13, 190–1, 207, 213–14, 220–4, 226–31, 233–6, 239–42, 244–5
 autosomal recessive polycystic kidney disease (AKPKD) 54–6
 AVF *see* arteriovenous fistula
 azathioprine 15–16, 289–94, 328–9
 B cells 257–62
 back pain 102–4
 bacteria 53, 178–9, 182–4, 194–5, 198–9, 216–19, 237–42, 253, 300, 334
 base 39–40
 basement membrane 26–57, 103, 108, 209–45
 basilic vein 171–202
 basiliximab IL2-RA 290–4
 basophils, definition 146–7
 BCG 330
 BCOP *see* blood colloid osmotic pressure
 Beck Depression Inventory 84
 behavioural change, transtheoretical model of behaviour change 89
 belatacept 294
 Bence Jones protein 152
 benzylpenicillin 32
 bereavement services 317–18
 bicarbonate 26, 29, 30, 40–2, 106, 126, 129, 140, 143, 185–8, 192–5, 226–31, 305, 322–35
 bicarbonate buffering system 40–2, 126–7
 bile 144–5, 151
 biliary tract 102
 bilirubin 144–5
 biochemical markers, acute kidney injury (AKI) 98–9
 biocompatibility issues, dialysers 181–2
 bioelectrical impedance 359
 biohazard labels 139
 bioimpedance concepts 193
 biotin 355–6
 BK (polyoma) virus 295–7, 301
 blindness 13
 BlogSpot 70–4
 blood 98–9, 137–50, 170–202, 278–80, 286–8, 321–35, 347–50, 367–8
 blood cells 127, 210–45
 blood colloid osmotic pressure (BCOP) 28, 47
 blood leak complications 200
 blood pressure 24–57, 61–2, 86, 120–1, 123–6, 172–202, 233, 279–80, 321–35, 340–3, 346, 386
 blood pumps 4, 168–202
 blood supply 27–9, 35–6, 56–7, 99–100, 101, 209–14
 blood tests 98–9, 139–50, 192–5, 278–80, 286–8, 298, 321–35, 347–50, 367–8
 blood transfusions, transplantation 15–16
 blood in the urine 151–2
 blood-stained effluent problems, PD 237
 BMI 340–3, 348–50, 359–65, 374
 body composition assessment techniques, renal nutrition 348, 358, 359–65, 374
 body fluid osmolality 24–57, 97–8, 99–113, 128, 151, 165–202, 208–45, 353–6
 body fluid volume 24–57, 97–8, 99–113, 128, 176–202, 233, 245, 321–35, 338, 348–50, 353–6
 body image, psychological perspectives 86–7, 94, 245
 Boen, S.T. 11
 bones 36–7, 126–7, 129, 142, 158–9, 299, 315–16, 325–6, 340–1, 344–5, 388
 bottles, CAPD 12–13
 Bowman's capsule 21–57
 brachial artery 171–202
 brachial vein 171–202
 brain stem death 262–3, 266
 Brescia, Michael 8
 British Association of Paediatric Nephrology 335
 British Medical Association (BMA) 121, 284
 British Transplantation Society 278–80
 bruising 98
 bruit and thrill 172
 bulk-phase reabsorption 30–1
 burns 100–4, 141–2
 'button hole' technique 62, 173–7
 buying/selling debates, donors 276
 bypass operations 44
 C-reactive protein (CRP) 149, 154, 343, 360, 363–4
 C4d deposition 295–7
 caffeine 317
 calcineurin inhibitors (CNIs) 253, 290–4, 328–9
 calcitonin 37–9
 calcitriol 37–9, 344–5
 calcium 26, 29, 36–9, 105, 126–30, 142, 159, 182–4, 185–8, 192–5, 198, 211–14, 226–31, 299, 317–18, 322–35, 342–68
 calyx 21–57
 cancers 52, 76, 99, 145, 150, 162–3, 251, 254–6, 263–5, 303, 356, 360, 365–7
Candida 239–42, 298–9, 300
 cannulae 7–8, 62–4, 137–9, 171–202
 CANUSA study 361
 CAPD *see* continuous ambulatory peritoneal dialysis
 capillary endothelium 209–45
 capillary-flow dialysers 5–6, 179–88
 capsaicin cream 317
 capsular hydrostatic pressure (CHP) 28–57
 carbon dioxide (CO₂) 40–2
 carbon filtration 183–4
 carbonic acid (H₂CO₃) 40–2
 carbonic anhydrase 40–2
 cardio-pulmonary resuscitation (CPR) 313–14
 cardiorespiratory status, transplantation 297

- cardiovascular disease (CVD) 43–4, 49, 89–90, 100–5, 118–20, 122–3, 132–3, 142, 144–5, 195–6, 224–5, 231–3, 235–6, 252–5, 299, 324, 340–68
 care bundles 390
 Care, Compassion and Communication ‘three C’s’ 64, 68, 78–9, 130–3, 201–2, 310–12, 381–91
 Care Quality Commission in England 60
 carers 6, 11, 59–79, 80–94, 130–3, 307–18, 320–35
 Caring for Australians with Renal Impairment (CARI) 88, 131–3
 carotid artery 2
 Carrel, Alix 13–14
 casts 153
 CAT *see* computed axial tomography
 catheters 10–13, 44, 61–79, 86–7, 133, 152, 162–3, 170–202, 212–45, 271–3, 298–9, 303, 330–5, 390
 cellophane, dialysis history 3
 cellulose acetate, dialysis history 3–6
 cellulose membranes, concepts 3–6, 180–8
 central nervous system (CNS), disorders 129
 central venous catheter (CVC) 83, 86, 170–1, 177–202, 287, 298–9, 390
 central venous pressure (CVP) 101, 297–301
 Centre for Epidemiologic Studies Depression Scale 84
 cephalosporins 103–4
 chickenpox *see* varicella zoster virus
 children 29, 48, 50–3, 54–6, 82–94, 150–3, 156–8, 224, 261–2, 277–9, 320–37, 367–8, 385–6
 AKI 332–5
 CKD 321–35
 concepts 320–35
 HD 331–5
 nursing guidelines 320–35, 385
 PD 330–5
 physiology in children 321–35
 renal nutrition 323–6, 367–8
 statistics 320–35
 weight 321, 323–6, 367–8
 chlorambucil 52
 chlorhexidine aqueous solution 178–9
 chloride 26, 29, 33–6, 185–8, 226–31
 chlorine 183–4
 chlorpheniramine 199, 317
 cholesterol 140, 144, 235–6, 342–3
 chromium 155–6, 355–6
 chronic allograft nephropathy (CAN), concepts 294–7, 305
 chronic kidney disease (CKD) 20, 43–57, 59–79, 80–96, 97–101, 116–35, 136–63, 207–45, 307–18, 320–35, 338–68, 384–91
 ciclosporin 15–16, 52, 103–4, 289–94, 299–301, 367–8
 Cimino, James 8
 citrate 179, 186–7
 CJD 263
 CKD *see* chronic kidney disease
 CKD Epidemiology Collaboration equation (CKD-EPI) 118, 154–5
 CKD stress inventory (CKDSI) 83
 CKD-EPI *see* CKD Epidemiology Collaboration equation
 clinical effectiveness, quality improvements in renal nursing 382, 384
 clopidogrel 157
 clotting of the blood lines and dialyser, complications 200
 CMV *see* cytomegalovirus
 co-efficient of ultrafiltration (KUF) 168–202
 coagulation 2–3, 4–5, 7–8, 48, 113, 127–8, 139, 145–6, 147, 156–7, 279–80
 Cockcroft-Gault equation 154
 coil dialyser dialysis history 6
 cold ischaemia 272–3
 collaborative approaches, healthcare professionals 83–4, 130–3
 collecting ducts 21–57
 collodion tubes, dialysis history 2–3
 colonic infections 24
 colour of urine 25, 26, 102, 151
 coma 42, 262–73
 communications 61–5, 68, 69, 78–87, 130–3, 201–2, 310–12, 381–91
 comorbidities 89–90, 118–19, 133, 308, 311, 315–18, 356–9, 367–8
 complement studies, definition 145
 complications
 AVF 175–7, 390
 HD 171–2, 194–202, 331–5
 PD 207, 211, 214, 216–19, 231, 235–42, 330–5, 346, 357–9, 390
 transplantation 64–5, 68, 86, 91–2, 158, 161, 250–2, 289–301, 329, 365–7
 computed axial tomography (CAT), concepts 160
 computed tomography (CT), concepts 160–1, 279
 concentration gradients 166–202, 208–14, 234
 concentration of urine 24–5, 27–9, 32–3, 128, 151–3
 concurrent flows 168–202
 conduction *see* diffusion
 conservative management *see* nondialytic options
 constipation 216, 236, 299, 314–16, 346, 362–3
 contents of urine 26, 150–3
 continuous ambulatory peritoneal dialysis (CAPD) 1, 7, 12–13, 82–4, 92–4, 190–1, 207, 214, 220–5, 226–31, 239–45, 351–6
 continuous cyclar peritoneal dialysis (CCPD) 13, 221–3
 continuous haemodiafiltration (HDF) 108, 109–10, 111, 167–202, 333–4
 continuous haemodialysis (HD), AKI management 110, 111, 112
 continuous haemofiltration (HF), AKI management 108, 109–10
 continuous renal replacement therapy (CRRT) 98, 107, 108–13, 333–4
 CONTRAST study 170
 contrast-induced acute kidney injury (CI-AKI) 103
 convection 166–202, 210, 211–45
 convoluted tubules 21–57
 Coombs’ test 149
 coping strategies 80–94, 133, 190–1, 216–17, 278–9, 303, 317–18
 copper 182–4, 350–1, 355–6
 coroner, donors 269–70
 cortex 21–57, 102, 321
 cortical necrosis, concepts 102
 cortical nephrons 22–57
 corticosteroids 14–15, 48, 52–3, 57, 159, 290, 293–4, 299, 326–7, 328–9, 366–7
 counselling 94, 113, 202, 251, 256
 countercurrent mechanism of urinary concentration 32–3

- CPR *see* cardio-pulmonary resuscitation
- Cr EDTA GFR 154, 155–6
- cramps 196–8, 200
- creatine kinase, definition 145
- creatinine 24–57, 98–9, 104–5, 117–21, 140, 141, 152, 154–6, 163, 166–202, 211–45, 279–80, 296–7, 321–35, 347–50
- crescentic glomerulonephritis, concepts 50, 53
- cross-matching, transplantation 15–16, 260–2, 277–80, 286–8
- CRRT *see* continuous renal replacement therapy
- CT *see* computed tomography
- cultural care 90, 130–3
- culture-negative peritonitis 240, 241–2
- Cuprophan cellulose membrane 5–6, 180–8
- Cushing's disease 34
- cyclophosphamide 52
- cystitis 305
- cysts, polycystic kidney disease 43, 54–6, 252, 315–16
- cytomegalovirus (CMV) 254–5, 299, 300–1
- cytotoxic antibodies 14–15, 294–7
- daclizumab IL2-RA 290–4
- Dacron cuff 11, 218–19
- Darzi, Lord 381
- DDAVP 157
- deafness 243, 302
- Dean, Norman 11
- deceased donors 262–73, 283–5, 304–5
- decision-making 59–79, 81–94, 130–3, 201–2, 307, 310–18, 368
- dehydration 25, 29, 33–5, 141, 144, 151–3, 281–2, 297–8, 305, 324
- dental state 253, 255
- Department of Health 59, 80, 116–17, 120–1, 170–1, 283–5, 310, 320–35, 381, 384–91
- depression 37, 66, 80, 81, 84–94, 274, 282, 286, 314–15, 357, 362
- dermatological disorders, management 127–8, 199, 303, 314–18
- dextrose 9–10, 12–13, 105, 225, 298, 353–6
- diabetes mellitus 8, 13, 30–2, 43–57, 89, 103–5, 116–17, 120, 123, 125–6, 141, 151–3, 201–2, 212, 223–5, 239, 251–3, 266, 287–8, 303–5, 308, 315–16, 339–43, 365–7, 386
- diabetes insipidus 32, 151
- diabetes mellitus 30, 43–57, 116–17, 120, 123, 125–6, 141, 151, 201–2, 212, 223–5, 239, 251–3, 266, 287–8, 303–5, 308, 315–16, 339–41, 343, 365–7, 386
- diabetic nephropathy 49–50, 223–5, 350–1
- diagnoses 84–5, 98–9, 100, 104–5, 117–19, 122–33, 136–63, 228, 239, 315–16, 323
- dialysate 166–70, 185–202, 208–45, 353–6, 364–5
- dialysers 2–9, 60–79, 165–202
- dialysis 1–19, 59–79, 82–4, 99, 105, 108–13, 116–17, 129–33, 141, 165–202, 207–45, 286–8, 307, 312–18, 329–35, 351–6, 384–91
see also haemodialysis; peritoneal dialysis
- diamorphine 317
- diarrhoea 24, 36, 101, 127, 142, 198
- diffuse intercapillary glomerulosclerosis 49
- diffusion concepts 29–31, 165–202, 208–45
- diffusion reabsorption mechanism, concepts 29–31
- dilution of urine 24–5, 32–3, 151–3
- dipstick tests, urine 151–3
- disability benefits, transplantation 93–4
- disequilibrium complications 197–8, 200
- distal convoluted tubule 21–57
- diuresis 25, 33–5
- diuretics 25, 36, 37, 47–8, 52–3, 128, 142, 324–35, 341–2
- dizziness 197
- DNA 292–4, 328–9, 364
- dogs, transplantation history 14
- donation after brain death (DBD) 262–73
- donation after circulatory death (DCD) 262–3, 272–3
- donor cards 265–7, 273, 284
- donors 13–14, 16, 64, 65–6, 71, 90–4, 249–305, 327–8
- Doolan, Paul 10
- Doolan PD technique 10
- DOPPS study 169–70, 355–6
- dosage, dialysis 6, 8–9, 11, 12–13, 61–3, 66–7, 82–5, 92–3, 109–13, 132–3, 188–202, 219–23
- double mini PETs 212–14
- drug metabolites 26, 31–3, 46, 101–4
- drug overdoses 4, 102–4
- 'dry weight' concepts 192–3, 196
- dual energy x-ray absorptiometry (DEXA) 158–9, 170, 347, 356–60
- Dubost procedure 14
- ducts 21–57
- dwell times, PD principles 9–10, 12–13, 212–45
- dyspnoea, symptoms towards the end-of-life 314–18
- dysrhythmias 98
- early adulthood 320–35
see also children
- early-stage CKD disclosures to patients 121–2
- 'Eat Well Plate' 366–7
- EBPG *see* European Best Practice Guidelines
- eclampsia of pregnancy 100–4
- EDTNA *see* European Dialysis and Transplant Nurses Association
- education 74–9, 83–4, 87–9, 92–4, 124–33, 138, 174–202, 207, 238–9, 242–5, 254–6, 268, 302–5, 323–35, 389–91
- efferent arteriole 27–57
- effluent specimens, PD 239–42
- eGFR 29, 81–2, 104–5, 117–19, 122, 123–4, 126, 130, 133, 141, 154–6, 315–16, 387
- elderly patients 8, 13, 103, 121–2
- electrolyte imbalance complications 197–8
- electrolytes 9–10, 15, 22–57, 97–8, 105–7, 113, 139, 168–202, 210–45, 281–2, 297–8, 321–35, 365–7
- embolism 44
- emotions 67, 80, 81–94, 97–8, 122, 130, 174, 281, 285, 286–8, 297–9, 301, 311–18, 323
- employment guidelines 245, 303
- empowerment 61–2, 81–94, 124–5, 130–3, 201–2, 310–18, 368

- ENABLE-CKD project 76–8
 encapsulating sclerosing peritonitis (EPS) 234
 encephalitis 301
 end-of-life care 90, 117, 307–18
 end-stage renal disease (ESRD) 72, 82, 85–94, 104–5, 136–7, 140, 153–4, 177–8, 223–5, 305, 307–18
 endothelial lining of the glomerular capillaries 26–57, 296–7
 energy requirements 323–6, 340–68
 Engelberg, Joseph 6
 eosinophils, definition 146–7, 153
 epigastric artery 209–45
 epinephrine adrenaline 159, 199
 epithelial cells 30
 equipment overview, HD 179–88
Equity and Excellence: Liberating the NHS (Department of Health White Paper 2010) 59, 381
 ERCA *see* European Renal Care Association
 erectile dysfunction 85–7, 129–30
 ERF *see* established renal failure
 erythrocytes 29, 42, 127, 145–6, 199–202
 erythropoietin 16, 24, 42, 56, 127, 130, 136, 147–50, 316, 347
 erythropoietin stimulating agents (ESAs), concepts 136, 148–50
Escherichia coli 239, 334
 ESRD/ESKD *see* end-stage renal disease
 established renal failure (ERF) 16, 20, 43–57, 97–8, 116–33, 207–45, 249–50, 321–35, 338–68
 ethics 252, 265–6, 274–6, 285, 311–12
 ethnicity 117–20, 133, 265–6, 267, 268, 353
 ethylene oxide (ETO) 185, 198–9
 Europe, dialysis history 4
 European APD Outcome Study (EAPOS) 233
 European Best Practice Guidelines (EBPG) 88, 131–3, 194–5, 238, 354–6, 366–7, 389
 European Council Directive 2010/32/EU (sharps directive) 137–9
 European Dialysis and Transplant Nurses Association/European Renal Care Association (EDTNA/ERCA) 339–40, 387–91
 European Society for Clinical Nutrition and Metabolism (ESPEN) 358–9
 evidence-based activities 76–8, 82, 390
 excretion 21–57, 140–53, 154–6
 exit-site care PD 218–19, 235–6, 238–42, 244–5
 exit-site infections, PD 241–2
 experiences, transplantation 60–3, 64–5, 67–79, 82, 89, 92–4
 extraperitoneal transplantation technique 14
 extraversion 85
 Facebook 70–4
 faecal occult blood test (FOBT) 150
 faeces 25
 family members 6, 76–94, 97–113, 130–3, 253–6, 265–7, 273–82, 299, 310–18, 320–35, 381–91
 family-centred approaches, AKI 97–8
 Fast PET 212–14
 fatigue symptoms towards the end-of-life 314–18
 femoral vein 8, 162–3, 170–1, 177–202
 fentanyl 317
 Fenton, Stanley 11–12
 ferritin 148, 194–5, 325–6, 347, 355–6, 360
 fever 102–4
 fibrin formation problems 236
 fibromuscular dysplasia 44
 filtration 26–57, 165–202
 first-use syndrome, dialysers 198–9, 390
 flow meters 8–9
 fluid management 234–5, 245, 324–6
 fluid retention 43
 flush before fill systems 12–13, 238
 focal segmental glomerulosclerosis, concepts 50, 53, 350–1
 folic acid 148–9, 343, 347, 349–50, 355–6
 food sources, protein 349
 Food Standards Agency (FSA) 342
 food supplementation 323–6, 363–4
 foot examinations 201, 386
 France, transplantations 13–15
 free-standing units 8–9
 frequency/duration of dialysis 6, 8–9, 11, 12–13, 61–3, 66–7, 82–5, 92–3, 109–13, 132–3, 188–202, 219–23, 234–5
 fresh frozen plasma (FFP) 113
 furosemide 128
 full blood count (FBC), definition 146, 147
 fungal infections 240, 241–2, 300
 Galen 9
 gall-bladder trocars 10–11
 gamma glutamyl-transpeptidase 144
 Ganter, George 9–10
 gastrointestinal disorders 36, 48, 98, 101, 102–4, 106, 127, 141, 150, 198, 301, 323–6, 356–7, 362–3
 gastrointestinal haemorrhage 102
 General Medical Services Contract (GMS) 120–1
 General Practitioners (GPs) 72, 120–1
 gentamycin 179
 Georgetown University 12
 Germany, transplantations 13–14, 283–5
 GFR *see* glomerular filtration rate
 Giovanetti diet 338–9
 glomerular blood hydrostatic pressure (GBHP) 28–57
 glomerular filtration 26–9
 glomerular filtration rate (GFR) 28–57, 81–2, 99–113, 117–19, 122, 123–4, 126, 130, 133, 141, 153–6, 279, 315–16, 321, 340, 345–7
 glomerulonephritis 43, 46, 50–3, 100–4, 151–3, 251, 322–3
 glomerulus 21–57, 99–113, 155, 251
 glucose 9–10, 29–30, 49–50, 123–6, 140, 143, 151–3, 185–8, 201, 208–45, 343, 357–9, 367–8
 glycaemia 120–1, 123–4
 glycosylated haemoglobin (HbA1c) 49, 125–6, 143, 201–2, 343
 GMS *see* General Medical Services Contract
 goat donors 13
 gold 52
 Goodpasture's syndrome 53, 145, 251
 Gottscho, Ira 11
 GPs *see* General Practitioners
 Graham, Thomas 1–2
 growth of children 321, 323, 325–6, 367–8
 Guarino, John 6
 Guillain-Barré syndrome 112

- guilt feelings, transplantation 93–4, 256, 285–6, 299
- gut wall infections 239–42
- Gutch 11
- Guthrie, B. 14
- Haas, Georg 2
- haematinics 148, 150
- haematocrit (HCT) 145–6
- haematogenous peritonitis infection route 239–42
- haematological tests 145–6, 279–80, 286–8
- haematoma 137–9, 156–8
- haematuria 53, 56–7, 150, 151–63, 304
- haemodiafiltration (HDF) 108, 109–10, 111, 167–202, 332–4
- haemodialysis (HD) 1–9, 10, 12, 60–79, 82–9, 108–13, 165–206, 299, 308, 331–5, 338–40, 351–68, 384–91
- definition 165–8
- dosage 6, 8–9, 11, 12–13, 61–3, 66–7, 82–5, 92–3, 109–13, 132–3, 188–202
- haemofiltration 108, 109–10, 166–202
- haemoglobin (Hb) 29, 40, 125–6, 145–6, 194–5, 201–2, 279–80, 316, 325–6, 347–50
- haemolysis 148, 199–202
- haemolytic uraemic syndrome (HUS) 334–5
- Hale, Stephen 9
- handwashing guidelines 238–9, 298–9
- hangovers, dehydration 25
- haptoglobins 149
- hard water 198
- Hartman's solution 15
- HD *see* haemodialysis
- HDF *see* continuous haemodiafiltration; haemodiafiltration
- HDL cholesterol, normal values 144
- headaches 98, 192–5, 197–8, 323
- Health Foundation 76–8
- Health and Safety Executive (HSE) 137
- healthcare professionals 78, 80–94, 116–33, 137–63, 174–202, 207, 238, 242–5, 254–6, 309–18, 334–5, 385–91
- Helicobacter pylori* 253
- helper T cells, concepts 258–62
- Henoch–Schönlein purpura 51, 52, 326–7
- heparin anticoagulant 2–3, 4–5, 7–8, 48, 139–40, 156–7, 163, 179, 187–8, 236, 240–3, 299
- hepatitis B 52, 53, 137, 145, 194–5, 251–2, 255, 264, 330
- hepatitis C 53, 137, 145, 194–5, 251–2, 255, 264, 388
- hepato-renal syndrome 102
- herbicides 183
- hernias 235–6
- herpes viruses 255, 301
- Hess and McGuigan 2
- high sodium 185–8
- high-fibre foods 346, 367
- hilus 20–57
- Hiroshima atomic bomb 15
- hirsutism 86, 94
- hirudin anticoagulant 2
- histocompatibility antigens, definition 259–62
- history of dialysis and transplantation 1–19, 207, 249–50, 338–40, 351–6
- HIV 53, 137, 145, 194–5, 251–2, 263–4
- HLA *see* human leukocyte antigen
- holidays 62, 245, 303
- hollow-fibre dialysers 6, 179–88
- home haemodialysis (HHD) 6–7, 9, 16–17, 62–79, 88–9, 131–3, 190–1, 387–91
- home peritoneal dialysis 11–12, 212–14, 220–3, 224, 242–5, 387–91
- Hope, J. 80–1
- hormones 24, 26, 30–57, 86–7, 127–8
- hospice care 90
- hot Roman baths, dialysis history 1, 16
- HPV4 330
- HTA *see* Human Tissue Authority
- Hull Laboratory, Chicago 14
- human chorionic gonadotrophin (hCG) 26
- human leukocyte antigen (HLA), definition 259–62, 277–8, 295–7
- Human Tissue Authority (HTA) 265, 276
- Hume, D.M. 14
- HUS *see* haemolytic uraemic syndrome
- hyaline arteriolar sclerosis 44, 49, 51, 153
- hydration 281–2, 297–8
- hydrocortisone 199
- hydrogen 31, 36, 39–42, 106, 129, 143
- hydrostatic pressure, concepts 166–202, 210
- hygiene standards, patient and carer involvement 64–5
- hyperacute rejections, concepts 294–7
- hypercalcaemia, aetiologies 37, 39, 142, 198, 344–5
- hyperfiltration/hyperperfusion hypothesis 339
- hyperglycaemia 49–50, 105, 343, 353–6, 364–5
- hyperkalaemia 36, 42, 98, 105–6, 108–13, 128–9, 142, 198, 199, 341–2, 345–6
- hyperlipidaemia 48, 327, 341, 342–3, 350–1, 353–6, 366–7
- hypernatraemia 141, 198, 235
- hyperosmotic medullary interstitium 32–3
- hyperphosphataemia 325–6, 338, 341, 344–5, 355
- hyperproteinaemia 144
- hypertension 33–5, 42–57, 98, 100–4, 117, 120, 152, 182–4, 192–5, 200, 224, 231–3, 235, 266, 324–35, 339–42, 350–1, 366–7
- hypertonic solutions 226–31, 234
- hypervolaemia 231
- hypnotics 317
- hypoalbuminaemia 47–8, 350–1, 360
- hypocalcaemia, aetiologies 37, 39, 142, 344–5
- hypoglycaemia 49–50, 105
- hypokalaemia, aetiologies 36, 142, 198
- hyponatraemia 141, 198
- hypoperfusion 99–100, 105–7
- hypoproteinaemia 48, 144
- hypotension 33–5, 51, 172, 182–4, 185–6, 192–8, 200, 300
- hypothalamus, osmoreceptors 33–5
- hypothyroidism 52
- hypovolaemia 99–100, 102–4, 195–6, 231, 333
- hypoxia 42, 105, 196–7

- ibuprofen 123
 IBW *see* ideal body weight
 icodextrin 220, 224–5, 226–31,
 234–5, 353–6
 ideal body weight (IBW) 339–40,
 348–50, 351–6, 359–65, 374
 identical twins, transplantation
 history 14
 IDH *see* intradialytic hypotension
 IHI *see* Institute for Health
 Improvement
 iliac artery 288–9, 304
 iliac vein 288–9, 304
 immobilisation methods, catheters 219
 immune system 1, 13–17, 50–3,
 257–62, 289–97, 328–9, 350–1
 immunoglobulin IgA 52, 113, 145,
 251
 immunoglobulin IgG 145, 149
 immunoglobulins 52, 113, 145, 149,
 251, 350–1
 immunosuppression needs 14–17,
 48, 52–3, 57, 64–5, 68, 86–7,
 91–2, 127, 251, 254–6, 259–62,
 277–8, 289–94, 303–4, 328–9
 impressive versatility of urine 22–4
 in-patient care 64–79, 190–1
 induction immunosuppression,
 concepts 290–4
 infants 320–35
 see also children
 infection 8, 9–10, 12–13, 24, 50,
 53–6, 62, 101–4, 106, 107,
 140–1, 146–7, 163, 172–202,
 214–19, 237–42, 245, 251–6,
 263–5, 298–9, 300–1, 330–5, 390
 influenza 53, 126, 300
 information booklets for patients 78,
 82, 88–9, 130–1, 242–5, 302–5
 informed consent 90–1, 136, 265–7,
 273, 276, 284
 Inouye, William Y. 6
 insertion techniques, catheters
 217–18, 236–7
 Instant Messaging (IM) 70–4
 Institute for Health Improvement
 (IHI) 382–3, 390–1
 insulin 13, 36, 49–50, 105, 143,
 224–5, 305
 intensive care nurses 98
 intercostal artery 209–45
 interferon 103–4
 interleukin-1 293–4
 interleukin-2 103–4, 290–4, 296–7
 interleukin-6 343, 360
 interlobar arteries 27–57
 interlobar veins 27–57
 interlobular arteries 27–57
 intermittent haemodialfiltration, AKI
 management 108, 109, 333–4
 intermittent peritoneal dialysis (IPD),
 definition 12
 intra-arterial balloon catheters 44
 intradialytic hypotension (IDH),
 concepts 195–6
 intradialytic parenteral nutrition
 (IDPN) 364–5
 intraluminal peritonitis infection
 route 238–42
 intraperitoneal amino acid (IPAA)
 230, 362
 intraperitoneal (IP) insulin 225
 intravascular clotting, nephrotic
 syndrome 48
 intravenous urograms (IVUs),
 concepts 159
 investigations 98–9, 136–64, 191–5,
 278–80, 286–8, 298, 315–16,
 321–35, 347–50, 357–9, 367–8
 INVOLVE guidelines 78
 involvement, patient and carer
 involvement 59–79, 82, 124–33,
 171–202, 242–5, 302–5, 307–18
 iodine 157, 159, 162, 178–9, 218–19
 IPAA *see* intraperitoneal amino acid
 IPD *see* intermittent peritoneal
 dialysis
 iron 148, 316, 325–6, 347, 349–50,
 355–6
 islet cell transplantation 304–5
 ISO standards for dialysis water
 182–4
 isoniazid 299
 Italy 12, 283
 jaundice 144–5
 Jehovah's Witnesses 265
 jugular vein 8, 62, 170–1, 177–202
 juxtaglomerular apparatus 35–6
 juxtamedullary nephrons 22–57
 KDIGO *see* Kidney Disease
 Improvement Global Outcomes
 KDOQI *see* National Kidney
 Foundation Kidney Disease
 Quality Outcome Initiative
 Kerr, Marion 99
 Kidney Disease Improvement Global
 Outcomes (KDIGO) 94, 104–5,
 107, 108, 113, 118–19, 194–5,
 341–2, 387–8
 kidney function tests, concepts
 153–6
 kidney patient associations
 (KPAs) 72
 Kidney Research and Education
 Initiative (KREI) 74–5
 Kidney Research UK 76–9
 kidney stones 142, 160
 kidneys 20–43, 97–8, 105, 117–18,
 139–40, 153–6, 244–5, 321
 Kiil, Fredrik 5–6
 Kiil parallel plate dialysers, history
 5–6, 7
 killer T cells, concepts 258–62
 Kimmelstiel-Wilson nodules 49
 kinins 34–5
 Kjellstrand, Carl 13
 Kolff, Willem 3–4, 10
 Kolff-Brigham dialysis machine,
 history 4–6
 Kop, P.S.M. 10
 Korean War 4, 7–8, 10
 Korzon, W. 4
 KPAs *see* kidney patient associations
 KREI *see* Kidney Research and
 Education Initiative
 Kussmaul's breathing
 (hyperventilation) 42, 51, 98, 192
 lactate dehydrogenase (LDH) 149,
 226–31
 Lasker cycler machine 11–12
 law 16, 265, 276, 284, 313–14
 laxatives 216, 236, 299, 316, 346
 LDL cholesterol, normal values 144,
 343
 lead 182–4
 learned helplessness 88–9
 leeches 2–3
 Leonards, Jack 5–6
 leptospirosis 101–2
 leukocytes 51–3, 127, 145–6, 153,
 257–62, 290–4
 lipids 48, 120–1, 140, 144, 235–6,
 327, 340–1, 342–3, 350–1,
 353–6, 366–7
 literacy skills 243
 lithium heparin 140

- liver 20, 37–8, 42, 48, 55, 101, 102, 105, 126, 140, 143, 144–5, 149, 154, 208–14, 251–2, 279–80, 286–8, 303–5, 334
 liver function tests (LFTs), concepts 144–5, 279–80, 286–8
 Living Donor Kidney Sharing Scheme 276–7
 living donors 90–4, 253–6, 273–82, 327–8
 local anaesthetics 172–3, 215–19
 local environments, countercurrent mechanism of urinary concentration 32–3
 locus of control 81
 London Acute Kidney Network (LAKIN) 99
 longitudinal changes to the peritoneal membrane, PD 233–4
 loops of Henle 21–57, 296
 low sodium 186–8
 low-molecular weight heparin (LMWH) 187–8
 Lucite hoods 4
 Luer connections 12
 lumbar artery 209–45, 281
 lungs 25
 lupus 46, 51, 57, 100–4, 145, 350–1
 lymphatic drainage, peritoneum 210–14, 234–6
 lymphocytes 50–3, 146–7, 258–62, 296–7
 MAC 347, 356–60
 macroalbuminuria 152
 macrophages 50–3, 296–7
 macula densa 35–6
 MAG 3 isotope 162
 magnesium 26, 36–7, 107, 113, 182–4, 185–8, 229–31, 317–18, 349–50
 magnetic resonance imaging (MRI), concepts 160–1, 279
 maintenance immunosuppression, concepts 291–4
 major calyx 21–57
 major histocompatibility complex (MHC), definition 259–62
 maladaptive coping responses 83, 85, 91–2
 Malinow, M.R. 4
 malnutrition *see* weight loss and malnutrition
 malnutrition-inflammation-atherosclerosis syndrome (MIA) 343, 358–9
 mammalian target of rapamycin inhibitor (m-TOR) 293–4
 MAMC 347, 356–61
 manganese 355–6
 manifold system, history 5–6
 mannitol 197
 mass-transfer concepts 166–202
 matching factors, donors 257–62, 277, 327–8
 Maxwell, Morton 10–11
 Maxwell PD technique 10–11
 MDRD *see* Modification of Diet in Renal Disease
 Medawar, Sir Peter 14–15
 medications 64–5, 68, 85–7, 91–2, 94, 97–8, 101–4, 123–33, 178–9, 193–5, 244–5, 252–3, 256, 289–99, 341–2, 357–9
 medulla 21–57, 102
 membrane overview 180–2, 198–200, 211–14, 233–4, 241–2
 membrane resistance factors, PD 211–14
 membranous glomerulonephritis, concepts 50
Meningococcus 101–2
 Mental Capacity Act 2005 313
 mercury 4
 Merrill, John P. 14
 mesangial proliferative nephritis 50, 52–3
 mesangiocapillary glomerulonephritis (MCGN) 50, 53
 mesothelium 208–45
 metformin 123, 163
 microalbuminuria 49–50, 118–21, 125–6, 152, 343
 microglobulin 168–202
 micronutrients, renal nutrition 349–50, 355–9
 microprocessors 8–9
 microscopy and culture, urine 153
 microvilli 208–45
 midazolam 156
 mild-to-moderate CKD 116–33
 Miller, David C. 14
 minerals 340–1, 349–50, 355–6
 mini PET 212–14
 minimal change glomerulonephritis, concepts 50, 52
 minor calyx 21–57
 mitochondria 30
 mobile phones 70–4
 The Model for Improvement 382
 Modification of Diet in Renal Disease (MDRD) 117–18, 154–6, 339–40, 353–6
 molecular weight concepts 27–9, 46, 110, 167–202, 211–45, 353
 Moncrief, Jack 12
 monitoring processes 62, 122–33, 176–202, 365
 monocytes 51–3, 146–7
 monosodium glutamate 342
 morbidity trends 8–9, 10, 132–3, 170, 193, 235, 252, 303–5, 307–8, 339, 348–9, 356–9
 morphine 316–17
 mortality trends 8–9, 10, 97–9, 102, 105, 113, 132–3, 168–70, 193, 195–6, 223–5, 234, 235, 252, 274, 303–5, 307–8, 339, 348–9, 355–9
 Mount Sinai Hospital 4
 MRI *see* magnetic resonance imaging
 MRSA 178–9, 194–5, 280, 287
 multidisciplinary models of care 87–9, 254–6, 280, 283–5, 312–18, 320–35, 368
 multiorgan donors 269–70
 multisystem diseases 46, 51, 56–7
 mupirocin 239–42
 muromab-CD3 monoclonal antibody 291–4
 Murray, Joseph E. 14
 muscle tone 36, 347–50, 359–65
 muscle wasting 48, 347–51, 356–65, 374–5
 Muslims 266
 MUST tool 357–9, 361–2
Mycobacterium 239–42
 mycophenolate mofetil 290–4, 328–9
 mycophenolic acid (MPA) 290–4
 myeloma 100–4, 112, 143
 myoglobin 100, 102, 151, 153
 naltrexone 317
 nasogastric and gastrostomy feeding 324–6, 363–4
 National Academy of Sciences 15
 National Confidential Enquiry into Patient Outcome and Death (NCEPOD) 99, 315

- National Institute for Health and Care Excellence (NICE) 7, 82, 123–7, 141, 144–6, 152, 234, 290, 330, 340–3, 358–9, 362–4, 366–7, 384, 385–7, 389–91
- National Institute for Health Research (NIHR) 78
- National Institutes of Health (NIH) 339
- National Kidney Foundation Kidney Disease Quality Outcome Initiative (KDOQI) 43, 118–21, 194–5, 339–40, 342–3, 344–5, 348–50, 358–9, 361, 368, 387–8
- National Research Council 15
- National Service Framework (NSF) for Renal Services 116–17, 120–1, 170–1, 309–10, 313, 320–1, 331–5, 384–5
- National Service Framework (NSF) for Renal Services: Working for Children, Young People and Maternity Services 320–1, 331–5, 385
- natriuresis 33–5
- nausea 48, 98, 101, 102–4, 106, 127, 182–4, 196–8, 201, 314–15, 316–18, 323, 334
- Nazi Germany, dialysis history 3
- Necheles, Heinrich 3
- needle sets 174–7
- needles 62–79, 137–9, 173–202
- negative pressure capacity 4
- negative pressure dialysers, history 4, 6, 8
- negative-feedback systems 30–1, 33–9, 42
- nephrectomy, surgical technique 280–1
- nephrons 21–57, 128, 153–6, 179
- nephrosclerosis 46
- nephrotic syndrome 46–8, 151, 326–7, 349–51
- nephrotoxicity 100–4, 163, 299–301
- net filtration pressure (NFP) 28–57
- Netherlands, dialysis history 10
- neutrophils 51–3, 146–7
- next of kin, donors 265
- NHS Blood and Transplant (NHSBT) 71, 261–2, 273, 277, 283–5
- NHS Connecting for Health Project Support 72
- NHS Institute for Innovation and Improvement Project Support 72, 87, 383, 390
- NHS Kidney Care Atlas of Variation 384
- NHS Kidney Care Project Support 72, 99, 385
- NHS Next Stage Review 381
- niacin 355–6
- NICE *see* National Institute for Health and Care Excellence
- NIH *see* National Institutes of Health
- ‘no decision about me, without me’ policy 59
- nominated nurses 62, 69, 201–2
- nonconcordance risk factors, medications 94, 256
- nondialytic options 86, 89–90, 307–19, 323–6
- normal values 117–18, 139–53, 321–2
- Norway 5–6, 275–6, 283
- NSAIDs 52, 101–2, 103, 123–4, 157
- nurses 51, 61–79, 82, 86–7, 97–113, 116–33, 136–63, 165–202, 207–45, 254–305, 307–18, 320–35, 338–68, 374–80, 381–91
- nurses’ stations 69
- nutritional peritoneal dialysis 364
- nylon catheters 11
- nystatin 298–9
- obesity 8, 253, 305, 348–9, 353–6, 365–7
- occult blood 150
- occupational therapists 317–18
- OCPD *see* optimised cycling
- peritoneal dialysis
- odour of urine 26
- oedema 10, 33–5, 46–8, 52–3, 98, 106, 192–5, 326–35, 348–51
- Olson, Edward 4
- omega-3 fatty acids 364
- ONS *see* oral nutritional support
- opioids 297, 316–18
- optimism, coping strategies 83
- optimised cycling peritoneal dialysis (OCPD) 222–3
- oral hygiene 253, 255
- oral nutritional support (ONS) 362–4, 368
- Oreopoulos, Dimitrios 11, 12
- osmoreceptors, hypothalamus 33–5
- osmosis 3, 24–57, 128, 165–202, 208–45, 353–6
- osmotic pressure 3, 24–57, 128, 165–202, 208–45
- osteodystrophy 159, 315–16
- out-patient care 64–79
- overnight dialysis, history 6
- ox bladders, dialysis history 1–2
- Package of Innovation (POI) for Managing Kidney Disease in Primary Care 124–5
- pain management 297, 314–18
- palliative care 2–3, 89–90, 307–18, 341
- Palmer, Russell 4, 11
- pancreas 143, 303–5
- pancreas-kidney transplantations 303–5
- pancreatitis 304–5
- pantothenic acid 355–6
- papillary necrosis 49
- paracetamol 102, 237, 316–18
- parallel plate dialysers 5–6, 179–80
- parathyroid hormone (PTH) 30–1, 37–9, 86–7, 106, 126–7, 130, 142, 148, 152, 317–18, 325–6, 344–5, 348–50, 357
- partial thromboplastin time (PTT) 147
- patient advisory groups 76–8
- patient safety 137–9, 382–7
- patients 59–79, 80–96, 124–33, 136–64, 171–202, 207–45, 302–5, 307–18, 320–35, 368, 381–91
- PD *see* peritoneal dialysis
- pedicels 26–57
- peer reviews 63–4
- penicillamine 52, 103
- Penn’s paper 251
- peptic ulcers 253
- percutaneous access 83, 86, 170–1, 177–202
- perfusion, prerenal AKI 99–100, 101, 105–7
- pericarditis 108
- periluminal peritonitis infection route 238–42
- peritoneal cavity 3, 208–45

peritoneal dialysis (PD) 1, 9–13, 16–17, 82, 83–4, 88–9, 133, 190–1, 207–48, 330–5, 346, 351–68, 384–91
see also assisted PD; automated PD; catheters; continuous ambulatory...; continuous cycle...; dialysis; home...; optimised cycling...; tidal PD definition 9, 82, 83–4, 207–14, 353 Peritoneal Equilibrium Test (PET) 212–14, 220, 330–1 peritoneal interstitium 209–45 peritoneal lavage 240–2 peritoneal membrane 208–45 peritoneal permeability measurements 212–14, 241–2 peritoneum 3, 208–45, 353–6 peritonitis 10–13, 210, 211–12, 216–17, 219, 228–31, 235–45, 330–1, 357–9 peritubular capillaries 27–57 permcats 61–79 permissions, donors 265–7, 273, 276, 284 personal care plans 64, 90 personality traits 85, 94 pesticides 183 PET *see* Peritoneal Equilibrium Test Peter Bent Brigham Hospital in Boston 4, 14 pethidine 297 pH 26, 39–42, 126, 129, 229–31 phagocytes 240–2 phlebotomy 137–9, 170–202 phosphate 26, 29, 30, 36–42, 107, 126–7, 130, 140, 142–3, 159, 194–5, 236, 317–18, 322–35, 338–68, 375–80 physical exercise 43, 64, 94, 123–4, 152, 154, 163, 235–7, 245, 340–2, 347–8, 367–8 physiological sodium 185–8 physiology 20–58, 185–8, 208–14, 321–35, 353–6 Picolax 216 pig donors 13, 284–5 pituitary glands 32 Plan-Do-Study-Act cycles (PDSA) 382 planning, nondialytic options 313–18 plasma exchange, AKI management 110–13

plasma proteins 40 plasma total proteins, normal values 144–5 plasmapheresis 57 plastic mesh sleeves, dialysis history 6 plate dialysers, history 5–6 platelets 113, 127–8, 145–6, 147, 295–7 pleural effusions 98 pneumonia 98, 126, 300–1 podocytes 26–57 poisons 46 polyarteritis nodosa, concepts 57 polycystic kidney disease 43, 54–6, 124, 252, 315–16 polyethylene catheters, dialysis history 10–11 polytetrafluoroethylene (PTFE) 176 polyuria 128, 151–3, 323, 324–35 polyvinylchloride (PVC) 12 Popovich, Robert 12 position for the transplantation kidney 288–9 positive pressure dialysers, history 6, 8 post-transplant follow-up, patient and carer involvement 64–5, 68, 91–4 postdilution, predilution debate 169–70 posterior pituitary gland, vasopressin antidiuretic hormone (ADH) 25, 30–1, 32–5 postinfection glomerulonephritis 50, 53 postoperative care 218–19, 235–6, 238–42, 281–2, 289–94, 297–301, 365–7 postrenal AKI, concepts 99–100, 101, 103–4, 333–5 potassium 4, 26, 29, 30–1, 36, 65, 68, 105, 107, 109–13, 128, 130, 140, 141–2, 185–8, 192–6, 198, 200, 211–14, 322–35, 340–68, 375–80 potassium chloride (KCl) 342 povidone-iodine 178–9, 218–19 powerlessness 81–94 PPI *see* public and patient involvement predialysis 59–79, 130–3, 338–51 predilution, postdilution debate 169–70 prednisolone 15–16, 289–94, 326–7 pregnancy 26, 53, 100–4, 129–30, 153–4, 158, 161 pregnancy tests 26, 53 preinsertion preparations, catheters 216 preliminary tests, transplantation 64, 89, 252–3, 257–62, 270, 327–8 preoperative care 216–18, 280, 285–8 preparation for haemodialysis 184–5, 190–1 prerenal AKI, concepts 99–100, 101, 333–5 preservation methods, transplantation 15, 265, 271–3 pretransplantation preparations 253–7, 278–9, 329–30 primary care teams, CKD 119–33 primate donors 13–14 Prismaflex machine 110, 112 processed foods, high sodium contents 342 prophylactic antibiotics 216–18, 239–42, 298–9 prostacyclins 187–8 prostaglandins 34–5 prostatic hypertrophy 100–4 protein 2–3, 12, 27–57, 100–4, 106–7, 120, 122–4, 126, 140, 150, 151–63, 194–5, 211–14, 231–3, 251, 323–35, 338–68 protein carriers, concepts 29–30 protein catabolic rate (PCR) 232, 348–50, 357–9 protein energy wasting (PEW) 358–61 protein loss problems 235, 338–68 proteinuria 48, 52–3, 56–7, 120, 122–4, 150, 151–63, 251, 326–35, 339–40, 350–1, 357–9, 386 proton pump inhibitors (PPIs) 253, 298–9 proximal convoluted tubule 21–57 pruritis (itching) symptoms towards the end-of-life 314–18 pseudocyst 304 *Pseudomonas* 238–42 psychogenic polydipsia 24, 323 psychological perspectives 61, 65–8, 69, 76, 80–96, 130–3, 190–1, 216–17, 242–5, 249–50, 254–7, 274–5, 278, 282–3, 285–8, 299, 303, 311–18, 320–35, 368, 387

- psychosocial risks, transplantation 93–4
- PTH *see* parathyroid hormone
- Public Health Service Hospital Boston 14
- public and patient involvement (PPI) 76–7
- pulmonary embolism 100–4
- pulmonary oedema 10, 100–4
- pulse 193, 280
- Putnam, Tracy 9
- pyelonephritis 43, 49, 53–4, 153
- pyrexia 54, 239, 300–1
- quality improvements in renal nursing 43, 72, 76–9, 87, 94, 104–5, 107, 108, 113, 117, 118–21, 137–63, 194–5, 310–18, 339–40, 341–3, 344–5, 348–50, 358–9, 361, 368, 381–91
- quality of life (QoL) 8–9, 16, 80–1, 84–94, 136–7, 147–8, 231–3, 249–50, 254–6, 305, 309–18, 320–35, 365, 389
- Quality and Outcomes Framework (QOF) 120–1
- quinine sulphate 197
- Quinton, George 8
- radial artery-to-cephalic vein AV fistula 8, 170–202
- radiographic investigations, concepts 158–63, 279–80
- raised intraabdominal pressure problems, PD 235–6
- rapamycin 293–4
- rashes 102–4, 199
- RCN *see* Royal College of Nursing
- reabsorption 21–57, 128, 151–3, 226–31, 234–5
- red blood cells 29, 42, 127, 145–6, 150, 153, 199–202
- red cell count (RCC) 146, 150, 228
- referrals 123–4, 136
- reflective practices, nurses 69–70, 368, 382–91
- refusals, donors 266–7, 268, 273
- Registry reports, transplantation 15–16
- rejections 64–5, 68, 86, 91–2, 158, 161–2, 254–6, 260–2, 285, 289–97, 329
- relapsing peritonitis 241–2
- religions 90, 130–3, 265–6, 311, 314, 317–18
- removal conditions, catheters 219
- renal angiograms, concepts 162–3
- renal artery 27–57, 161, 162–3, 271–3, 281, 288–9, 299–300
- renal artery stenosis 43, 44–5, 60–1, 100–4, 123–4, 129, 162, 175–7, 300
- Renal Association 117, 120, 131–3, 170–1, 177–8, 184, 194–5, 199, 201, 214, 229, 233, 279, 341–3, 344–5, 359, 387–91
- renal disease processes 20, 26, 33–7, 41–3, 59–79, 97–113, 130–3, 116–63, 266, 320–35
- renal doppler studies 162
- renal (intrinsic) AKI 99–103, 333–5
- renal nutrition 2–3, 8–9, 12–13, 43, 48, 65, 82, 86–7, 94, 106–7, 124–5, 126–7, 182, 201, 224–5, 232, 235, 245, 299, 303, 316–26, 338–80
- Renal Nutrition Group of the BDA 340–1
- Renal Patient Support Group (RPSG) 70–4
- renal pelvis 21–57
- renal replacement therapy (RRT) 8–9, 13–17, 80–94, 97–113, 116, 130–3, 136–7, 165–202, 307–8, 320–4, 327–35, 338–40, 351–68, 384–91
- renal scans, concepts 162
- renal vascular disease, ERF causes 43, 251, 390
- renal vein 27–57, 100–4, 161–2, 281, 288–9, 299–300
- renal vein thrombosis 100–4, 161–2, 299–300
- renal-specific formulae 323–6, 364–5
- renin production 24, 34–6, 43, 44–5, 47, 125–6
- renin–angiotensin–aldosterone pathway 34–6, 43, 44–5, 125–6
- renograms, concepts 162
- renovascular disease 43, 100–4
- requests, donors 265
- residual renal function (RRF) 232–3
- respiratory diseases 253, 255
- restless legs, symptoms towards the end-of-life 314–18
- resuscitation issues, nondialytic options 313–14
- reticulocytes 150
- retrograde pyelograms, concepts 160
- reverse osmosis 183–4
- rhabdomyolysis, concepts 100, 102, 145, 153
- Richardson, B.W. 2
- rifampicin 103–4, 151, 239–42
- RIFLE classification of AKI 104–5, 108
- RNA 292–4
- ‘rope ladder’ technique 62, 171–2, 173–7
- Rosenak, Stephen 10
- rotating drum dialyser, dialysis history 3–4
- Royal College of General Practitioners 72, 120
- Royal College of Nursing (RCN) 328–9, 332–5, 381–92
- Royal Free Hospital 6
- RPSG *see* Renal Patient Support Group
- RRT *see* renal replacement therapy
- rubber catheters 10–11
- Ruben, Richard 10
- ‘rule of six’ for a mature fistula 177
- Russia, transplantations 14
- salbutamol 105
- salicylates 2
- saline 113, 196–7, 298
- Salmonella* 101–2
- sampling needs 189–202, 239–42
- satellite haemodialysis, concepts 191
- Saunders, Dame Cicely 308
- Scribner, Belding 6, 8, 11
- secretion, concepts 31–3, 36
- segmented arteries 27–57
- SEIK *see* System for Early Identification of Kidney Disease
- Seldinger technique 218
- selective reabsorption 29
- self-care/self-management 78, 81–94, 124–6, 131–3, 138, 190–202, 238–9, 242–5, 302–5, 387–91
- self-efficacy 81, 88–9
- self-esteem 81–94
- self-harm 85, 91–2
- self-reliance, coping strategies 83
- self-respect, patient and carer involvement 60–79

selling of organs 276
 senna 151, 316
 sensitisation factors, transplantation 261
 sepsis 98–106, 109–13
 septic shock 98–106
 serological tests, definition 145
 serum iron 148
 serum protein electrophoresis 143
 Servelle procedure 14
 sexuality 85–7, 129–30, 245, 303
 Sheldon, Stanley 6
 sharps-related injuries 137–9
 sheep, dialysis history 3
 ‘shingles’ 301
 shock 98–104
 short supplies of organs, transplantation 16, 64, 250, 257, 282–5
 shoulder-pain problems, PD 237
 side effects, medications 85–7, 94, 101–4, 129–30, 262–73, 290–4
 Silastic synthetic polymer 8
 silicon peritoneal catheter 11
 simultaneous pancreas-kidney transplants (SPK) 303–5
 sirolimus 290–4, 328–9
 Skeggs, Leonard 5–6
 skeletal X-rays, concepts 159
 skin 14–15, 25, 127–8, 199, 303, 314–18
 Skype 74
 sleep apnoea 66
 sleep disturbances, symptoms towards the end-of-life 314–18
 smart phones 70–4
 smoking 43, 124, 125–6, 253, 255, 303, 341–3, 366, 367
 social media 70–4
 social support 81–94, 254–6, 278–9, 303, 309–18, 368, 387
 sodium 25, 26, 29–30, 33–5, 47, 65, 99–100, 105–6, 123–4, 128, 140, 141, 150–3, 182–4, 185–202, 226–31, 305, 322–35, 340–68, 375
 sodium bicarbonate 229–31
 sodium chloride 25, 33–5, 150–3, 229–31, 236
 sodium lactate 229–31
 sodium sieving 235
 solute movement concepts 166–202
 solvent drag *see* convection

special care on haemodialysis 201–2
 special needs, CAPD 13, 220
 specialist nurses 269–70
 specific gravity levels, urine 150–1
 spike connections, CAPD 12–13, 238
 spiritual care 90, 130–3, 311, 314, 317–18
 stainless-steel sump drains 10–11
 standardised peritoneal assessment (SPA) 212–14
Staphylococcus 53, 178–9, 216–18, 238–40
 Starling’s forces 28
 statins 299, 342–3
 steal syndrome 175–7
 stents 44–5, 300, 303
 sterile solutions, PD principles 9–11
 sterilisation methods, dialysers 184–5, 198–202
 stethoscopes 172
 Stewart, Richard 6
Streptococcus 53, 101–2, 238–40
 streptokinase 236
 stress 83–94
 strokes 43, 55, 90, 356
 structure and functions of the kidneys 20–43, 97–8, 105, 117–18, 139–40, 153–6, 244–5, 321
 subclavian vein 177–8
 subjective global assessment (SGA) 232, 348–50, 352, 357–9, 360–1, 374–5
 sugar 3
 suicidal ideation 85, 91
 superior mesenteric artery 209–45
 SV40 antigen 295–7, 301
 Swan-neck catheters 215–19
 swap/paired transplantation scheme 63, 90–1, 277
 sweating 24
 Sweden 4, 275, 283
 swimming and bathing advice, catheters 219
 Switzerland, transplants 15–16, 283–5
 symptoms towards the end-of-life 314–18
 synthetic membranes, concepts 180–8
 synthetic polymer chemistry, dialysis history 3, 8
 System for Early Identification of Kidney Disease (SEIK), definition 119–20
 systemic lupus erythematosus (SLE) 46, 51, 57, 100–4, 145, 350–1
 systemic sclerosis (scleroderma), concepts 57
 T cell depleting antibodies (TDAs) 290–7
 T cells 257–62, 290–7
 tacrolimus (FK506) 290, 292–4, 299–301, 328–9, 367
 Tamm–Horsfall proteins 153
 Tc DMSA isotope 162
 Tc DTPA isotope 162
 technological developments 70–4, 119–20, 160–3, 168–202, 220–3, 245, 308
 Teflon synthetic polymer 8
 temperatures of patients 193, 196, 279–80
 Tenckhoff catheter 11–12, 215–19, 348–50
 Teschan, Paul 4, 7–8
 tests 98–9, 136–64, 191–5, 279–80, 286–8, 298, 315–16, 321–35, 347–50, 357–9, 367–8
 Thalheimer, William 3
 thalidomide 317
 therapeutic plasma exchange (TPE), AKI management 110–13
 thirst mechanisms 24, 353–6
 thrombosis 44, 57, 100–4, 112, 161–3, 175–7, 285, 295–7, 299–300, 305
 thrombotic thrombocytopenic purpura (TTP) 112–13
 thyroid 37–9, 86–7
 tidal PD 222–3
 time of death, donors 263–5
 tiredness and lethargy 48, 323
 tissue typing, transplantation 15–16
 titanium connectors, CAPD 12–13
 TMP *see* transmembrane pressure
 Toronto Western catheters 215–19
 Toronto Western Hospital 11–12
 total body irradiation, immunosuppression methods 14–15
 total protein-creatinine ratio (TPCR), definition 154
 tourniquets 139, 177–202
 toxins 1–17, 23–57, 99–113, 140–1, 165–202, 208–45, 340
 TPE *see* therapeutic plasma exchange

- training 78, 83–4, 87–9, 130–3, 174–202, 207, 238, 242–5, 254–6, 334–5, 389–91
 tramadol 316–17
 transferrin saturation rate 148
 transition to adult services, children 334–5
 transmembrane pressure (TMP) 167–202
 transmural peritonitis infection route 239–42
 transplantation 1, 13–17, 59–79, 82, 89, 90–4, 133, 158, 161, 249–306, 327–35, 365–7
 transtheoretical model of behaviour change 89
 triglycerides 235–6, 343, 365, 366–7
 trisodium citrate 179, 186–7
 tru-cut kidney biopsy needles 157–8
 tuberculosis (TB) 253, 263–4, 299
 tubing 4–5, 7–8, 10–12, 168–202, 225, 236–7
 tubular urine, definition 28
 tumours 52, 162–3, 251
 tunnel infections, PD 242, 390
 Twitter 70–4
 Tygon tubing 7–8
- UK 59, 71, 80, 116–17, 120–1, 131–3, 170–1, 177–8, 184, 194–5, 199, 201, 214, 229, 233, 261–2, 277, 279, 282–94, 310, 320–35, 341–3, 344–5, 359, 381, 384–91
 UKM *see* urea kinetic modelling
 ulcers 253
 ultrafiltration capabilities 8, 29, 110–11, 165–202, 211–45, 353–6
 ultrasound 161–2, 176–7, 300
 unconditional gifts, donors 267, 284, 299
 University of Brighton Project Support 72
 University of Colorado 15
 University of Minnesota 13
 University of Washington Hospital 6, 11
 unrelated living donors 275–6
 uraemia 10, 82–4, 106, 108–13, 127–8, 129, 242–5, 312, 316–18, 340, 349–50, 357–9
 urea 6, 9, 24–57, 98, 140–1, 150–3, 166–202, 208–45, 286–8, 322–35, 347–50
 urea kinetic modelling (UKM) 188–90
 urea reduction ratio (URR) 188–90, 192–5
 ureteric stones 103–4, 160
 ureters 21–57, 158, 272–3, 281, 288–9, 298, 300
 uric acid 26, 143
 urinary bladder 21–57, 158–9, 216–18, 252–3, 288–9, 298, 304
 urinary tract 53–4, 56, 100–4, 156–8, 252–5, 305
 urine 22–57, 66–7, 98–113, 150–6, 298, 323, 324–35
 urokinase 179, 236
 urticaria 113, 160
 US 4, 6–8, 10–12, 13–15, 285, 382–3, 390–1
 vaccinations 303, 329–30
 vaginal peritonitis infection route 239–42
 valganciclovir 299, 301
 vancomycin 240–1
 varicella zoster virus (VZV) 255, 301, 330
 vasa recta vessels 27–57
 vascular access for haemodialysis 7–8, 83–4, 86, 132–3, 170–202, 223–4, 331–5, 390
 vascular access, types of 7–8, 83–4, 86, 132–3, 170–202, 214–19, 223–4, 331–5, 390
 vasculitis 44, 51, 100–4, 112
 vasodilation 34–5, 100
 vasopressin antidiuretic hormone (ADH) 25, 30–1, 32–5, 157
 vena cava 27–57, 271–3
 venepuncture 137–9
 venous stasis 48
 very low protein diet (VLVD) 338–40
 viral serology, definition 145
 visible blood pathways, dialysis history 6
 vitamin A 350, 355–6
 vitamin B1 349–50, 355–6
 vitamin B2 349–50, 355–6
 vitamin B6 347, 349–50, 355–6
 vitamin B12 148–9, 211–14, 343, 347, 349–50, 355–6
 vitamin C 347, 350, 355–6
 vitamin D 24, 37–9, 126–7, 142, 143, 159, 326, 344–5, 348–51
 vitamin E 350, 355–6
 vitamin K 350
 vitamins 24, 37–9, 126–7, 142, 143, 148–9, 159, 211–14, 326, 340, 344–5, 347, 349–50, 355–9
 VLVD *see* very low protein diet
 volume of urine 23–4, 98, 150–3
 vomiting 36, 48, 98, 101, 102–4, 106, 127, 142, 160, 182–4, 196–8, 201, 314–15, 316–18, 323–6, 334
 Voronoy transplantation 14
 waist/hip measurement ratio 343, 347–50
 Walter, Carl 4
 warfarin anticoagulant 156–7
 warm ischemia 272–3
 Warrick, Christopher 9
 water 22–57, 182–4, 198, 210–45
 weight 48, 106–7, 123–4, 126, 140–1, 192–5, 232, 321, 323–6, 338–68, 374–80
 weight loss and malnutrition 48, 106–7, 123–4, 126, 140–1, 192–5, 232, 338, 347–50, 356–9, 374–80
 wellbeing 81–94, 97–8, 189–90, 231–3, 242–5, 274–5
 wetting, children 323
 whistle-tip catheters 10–11
 white blood cells 51–3, 127, 145–7, 153, 239–42, 257–62, 290–4, 348–50
 withdrawal from dialysis 307, 312–18
 World Health Organization (WHO) 137, 308–9, 316, 349
 World Kidney Day 72–3
 World Kidney Day 2011–2012 72–3
 wound management 282, 298
 Wren, Christopher 7
 X-rays 158–63, 236, 279–80, 286–8, 325–6, 356–60
 xenotransplantation 284–5
 Y-system (flush before fill) 12–13, 238
 yellow skin tinge 128, 145
 Yorkshire AKI Networks Acute Kidney Injury Patient Pathway (AKIPP) 99
 zinc 182–4, 349–51, 355–9

